en
E-mail us
+1-609-604-8303
bd_global@crystalpharmatech.com
 cn

Preclinical and Tox Formulation Development

The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules?
Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules?
Efficient Preclinical Formulation Development for Poorly Soluble Compounds
Efficient Preclinical Formulation Development for Poorly Soluble Compounds
Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech
Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech
Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech
Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech
SMART Development of Pre-clinical Candidates
SMART Development of Pre-clinical Candidates
Services and Solutions
API Form and Solid-State Research Pre-formulation Studies Formulations for PK/Efficacy/Tox Studies Formulation Development Clinical and Commercial Manufacturing Analytical Chemistry Mol2Med™ Developability Assessment M4M™ Lead Op to FIH Biologics Analytical Services
Platforms
Quick Links
About Us Events
Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
U.S
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Sitemap
Privacy Policy Powered by: yinqingli.com
API Form and Solid-State Research
Solid Form Screening and Selection Amorphous Solid Dispersions Absolute Structure Determination Crystallization Screening and Development Chiral Separation by Crystallization Solid-State Characterization (FAST) Solid-State NMR Analysis
Analytical Chemistry
Analytical Method Development and Validation Drug Product Release Stability Study Compatibility Research API-Excipient-Packaging Release
Pre-formulation Studies
Formulation Development
Clinical and Commercial Manufacturing
Platforms
Solid Form Screening Solid Form Developability Evaluation Absolute Structure Determination Crystallization Process Development Conventional Oral Solid Dosage Forms Formulation Development for Poorly Water-Soluble Drugs Mini-Tablet
Quick Links
About Us Knowledge Hub Events
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303
Sitemap
Privacy Policy